TY  - JOUR
A1  - Edgecock, T. R.
A1  - Caretta, O.
A1  - Davenne, T.
A1  - Densam, C.
A1  - Fitton, M.
A1  - Kelliher, D.
A1  - Loveridge, P.
A1  - Machida, S.
A1  - Prior, C.
A1  - Rogers, C.
A1  - Rooney, M.
A1  - Thomason, J.
A1  - Wilcox, D.
A1  - Wildner, E.
A1  - Efthymiopoulos, I.
A1  - Garoby, R.
A1  - Gilardoni, S.
A1  - Hansen, C.
A1  - Benedetto, E.
A1  - Jensen, E.
A1  - Kosmicki, A.
A1  - Martini, M.
A1  - Osborne, J.
A1  - Prior, G.
A1  - Stora, T.
A1  - Melo Mendonca, T.
A1  - Vlachoudis, V.
A1  - Waaijer, C.
A1  - Cupial, P.
A1  - Chancé, A.
A1  - Longhin, A.
A1  - Payet, J.
A1  - Zito, M.
A1  - Baussan, E.
A1  - Bobeth, C.
A1  - Bouquerel, E.
A1  - Dracos, M.
A1  - Gaudiot, G.
A1  - Lepers, B.
A1  - Osswald, F.
A1  - Poussot, P.
A1  - Vassilopoulos, N.
A1  - Wurtz, J.
A1  - Zeter, V.
A1  - Bielski, J.
A1  - Kozien, M.
A1  - Lacny, L.
A1  - Skoczen, B.
A1  - Szybinski, B.
A1  - Ustrycka, A.
A1  - Wroblewski, A.
A1  - Marie-Jeanne, M.
A1  - Balint, P.
A1  - Fourel, C.
A1  - Giraud, J.
A1  - Jacob, J.
A1  - Lamy, T.
A1  - Latrasse, L.
A1  - Sortais, P.
A1  - Thuillier, T.
A1  - Mitrofanov, S.
A1  - Loiselet, M.
A1  - Keutgen, Th.
A1  - Delbar, Th.
A1  - Debray, F.
A1  - Trophine, C.
A1  - Veys, S.
A1  - Daversin, C.
A1  - Zorin, V.
A1  - Izotov, I.
A1  - Skalyga, V.
A1  - Burt, G.
A1  - Dexter, A. C.
A1  - Kravchuk, V. L.
A1  - Marchi, T.
A1  - Cinausero, M.
A1  - Gramegna, F.
A1  - De Angelis, G.
A1  - Prete, G.
A1  - Collazuol, G.
A1  - Laveder, M.
A1  - Mazzocco, M.
A1  - Mezzetto, M.
A1  - Signorini, C.
A1  - Vardaci, E.
A1  - Di Nitto, A.
A1  - Brondi, A.
A1  - La Rana, G.
A1  - Migliozzi, P.
A1  - Moro, R.
A1  - Palladino, V.
A1  - Gelli, N.
A1  - Berkovits, D.
A1  - Hass, M.
A1  - Hirsh, T. Y.
A1  - Schuhmann, M.
A1  - Stahl, A.
A1  - Wehner, J.
A1  - Bross, A.
A1  - Kopp, J.
A1  - Neuffer, D.
A1  - Wands, R.
A1  - Bayes, R.
A1  - Laing, A.
A1  - Soler, P.
A1  - Agarwalla, S. K.
A1  - Cervera Villanueva, A.
A1  - Donini, A.
A1  - Ghosh, T.
A1  - Gómez Cadenas, J. J.
A1  - Hernández, P.
A1  - Martín-Albo, J.
A1  - Mena, O.
A1  - Burguet-Castell, J.
A1  - Agostino, L.
A1  - Buizza-Avanzini, M.
A1  - Marafini, M.
A1  - Patzak, T.
A1  - Tonazzo, A.
A1  - Duchesneau, D.
A1  - Mosca, L.
A1  - Bogomilov, M.
A1  - Karadzhov, Y.
A1  - Matev, R.
A1  - Tsenov, R.
A1  - Akhmedov, E.
A1  - Blennow, M.
A1  - Lindner, M.
A1  - Schwetz, T.
A1  - Fernández Martinez, E.
A1  - Maltoni, M.
A1  - Menéndez, J.
A1  - Giunti, C.
A1  - González García, M. C.
A1  - Salvado, J.
A1  - Coloma, P.
A1  - Huber, P.
A1  - Li, T.
A1  - López Pavón, J.
A1  - Orme, C.
A1  - Pascoli, S.
A1  - Meloni, D.
A1  - Tang, J.
A1  - Winter, W.
A1  - Ohlsson, T.
A1  - Zhang, H.
A1  - Scotto-Lavina, L.
A1  - Terranova, F.
A1  - Bonesini, M.
A1  - Tortora, L.
A1  - Alekou, A.
A1  - Aslaninejad, M.
A1  - Bontoiu, C.
A1  - Kurup, A.
A1  - Jenner, L. J.
A1  - Long, K.
A1  - Pasternak, J.
A1  - Pozimski, J.
A1  - Back, J. J.
A1  - Harrison, P.
A1  - Beard, K.
A1  - Bogacz, A.
A1  - Berg, J. S.
A1  - Stratakis, D.
A1  - Witte, H.
A1  - Snopok, P.
A1  - Bliss, N.
A1  - Cordwell, M.
A1  - Moss, A.
A1  - Pattalwar, S.
A1  - Apollonio, M.
T1  - High intensity neutrino oscillation facilities in Europe
JF  - Physical Review Special Topics-Accelerators and Beams
N2  - The EUROnu project has studied three possible options for future, high intensity neutrino oscillation facilities in Europe. The first is a Super Beam, in which the neutrinos come from the decay of pions created by bombarding targets with a 4 MW proton beam from the CERN High Power Superconducting Proton Linac. The far detector for this facility is the 500 kt MEMPHYS water Cherenkov, located in the Frejus tunnel. The second facility is the Neutrino Factory, in which the neutrinos come from the decay of mu(+) and mu(-) beams in a storage ring. The far detector in this case is a 100 kt magnetized iron neutrino detector at a baseline of 2000 km. The third option is a Beta Beam, in which the neutrinos come from the decay of beta emitting isotopes, in particular He-6 and Ne-18, also stored in a ring. The far detector is also the MEMPHYS detector in the Frejus tunnel. EUROnu has undertaken conceptual designs of these facilities and studied the performance of the detectors. Based on this, it has determined the physics reach of each facility, in particular for the measurement of CP violation in the lepton sector, and estimated the cost of construction. These have demonstrated that the best facility to build is the Neutrino Factory. However, if a powerful proton driver is constructed for another purpose or if the MEMPHYS detector is built for astroparticle physics, the Super Beam also becomes very attractive.
KW  - EMMA
KW  - beta-beam
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-126611
VL  - 16
IS  - 2
ER  - 
TY  - JOUR
A1  - Bornstein, Stefan R.
A1  - Allolio, Bruno
A1  - Arlt, Wiebke
A1  - Barthel, Andreas
A1  - Don-Wauchope, Andrew
A1  - Hammer, Gary D.
A1  - Husebye, Eystein S.
A1  - Merke, Deborah P.
A1  - Murad, M. Hassan
A1  - Stratakis, Constantine A.
A1  - Torpy, David J.
T1  - Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline
JF  - Journal of Clinical Endocrinology & Metabolism
N2  - Objective: This clinical practice guideline addresses the diagnosis and treatment of primary adrenal insufficiency. Participants: The Task Force included a chair, selected by The Clinical Guidelines Subcommittee of the Endocrine Society, eight additional clinicians experienced with the disease, a methodologist, and a medical writer. The co-sponsoring associations (European Society of Endocrinology and the American Association for Clinical Chemistry) had participating members. The Task Force received no corporate funding or remuneration in connection with this review. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to determine the strength of recommendations and the quality of evidence. 
Consensus Process: The evidence used to formulate recommendations was derived from two commissioned systematic reviews as well as other published systematic reviews and studies identified by the Task Force. The guideline was reviewed and approved sequentially by the Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee, members responding to a web posting, and the Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. 
Conclusions: We recommend diagnostic tests for the exclusion of primary adrenal insufficiency in all patients with indicative clinical symptoms or signs. In particular, we suggest a low diagnostic (and therapeutic) threshold in acutely ill patients, as well as in patients with predisposing factors. This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension. We recommend a short corticotropin test (250 mu g) as the "gold standard" diagnostic tool to establish the diagnosis. If a short corticotropin test is not possible in the first instance, we recommend an initial screening procedure comprising the measurement of morning plasma ACTH and cortisol levels. Diagnosis of the underlying cause should include a validated assay of autoantibodies against 21-hydroxylase. In autoantibody-negative individuals, other causes should be sought. We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15-25 mg/d) or cortisone acetate replacement (20-35 mg/d) applied in two to three daily doses in adults. In children, hydrocortisone (similar to 8 mg/m\(^2\)/d) is recommended. Patients should be educated about stress dosing and equipped with a steroid card and glucocorticoid preparation for parenteral emergency administration. Follow-up should aim at monitoring appropriate dosing of corticosteroids and associated autoimmune diseases, particularly autoimmune thyroid disease.
KW  - glucocorticoid replacement therapy
KW  - Addison's disease
KW  - short Synacthen test
KW  - insulin tolerance test
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-190893
VL  - 101
IS  - 2
ER  -